NCT06693830 2026-01-23
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Columbia University
Phase NA Recruiting
Clinical Trials
11 trialsNCT07025785 2026-01-15
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase NA Recruiting
NCT07178847 2025-12-01
NeckTAR-IN
Centre Jean Perrin
Phase NA Recruiting
NCT07131059 2025-08-20
MRD-positive AML Clinical Study
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
NCT07003737 2025-06-04
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
First Affiliated Hospital of Zhejiang University
Phase NA Recruiting
NCT06930807 2025-04-16
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
Peking University People's Hospital
Phase NA Recruiting
NCT06885476 2025-03-20
Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase NA Recruiting
NCT06697483 2024-11-25
Risk Stratification and MRD-driven Maintenance for MM After ASCT
Peking University People's Hospital
Phase NA Recruiting
NCT06301425 2024-07-10
MRD Response-adapted Allo-HSCT for Adverse-risk AML
Peking University People's Hospital
Phase NA Recruiting
NCT06066905 2023-10-27
A Study of Chidamide With AZA in MRD Positive AML After Transplant
Guangdong Provincial People's Hospital
Phase NA Recruiting
NCT04179929 2022-02-18
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults
PETHEMA Foundation
Phase NA Recruiting